Eledon will be showcasing updated long-term results from the Phase 2 BESTOW trial of Tegoprubart at the upcoming ATC conference. The trial focuses on leveraging Tegoprubart to prevent rejection in kidney transplant patients. The data to be presented includes significant improvements in rejection rates, with a notable reduction of 30% compared to current standard treatments. This landmark research highlights the potential of Tegoprubart as a promising option in the field of transplant medicine.